EuroQuity Blog

Join the Women Entrepreneurs E-Pitch session on September 27th 2022 at 02:00 PM CEST

Meet five women entrepreneurs scouted by InvestEU Portal and EuroQuity on September 27th at 02:00 PM CEST



The InvestEU Portal and EuroQuity join forces and proudly present one e-pitch focused on solutions (co)-founded by women entrepreneurs, that will be held online on September 27th at 02:00 PM CEST.

InvestEU Portal is a programme of the European Commission. It is the online "marketplace" connecting EU-based startups across all economic sectors to investors worldwide. It provides greater visibility and options for entrepreneurs to reach out to investors and finance their projects. 

See you next September 27th at 02:00 PM CEST. If you have any questions, do not hesitate to contact mc.chumacerovalle@ext.bpifrance.fr
 

MedTech
Since 2017, we have been developing a fully implantable biventricular cardiac prosthesis, giving patients a better quality of life. Only 3% of patients with heart failure waiting for a transplant find a compatible donor. This is a global health issue, and yet there is only one artificial heart available on the market, using technology developed 40 years ago. Our solutions aim to make technological innovations available to patients with heart failure and other basic needs not being met.| Customers: 129 000 patients - potential worldwide | TAM: EUR 16 Bn | SAM: EUR 500Mn - 1 Bn | Pre-seed | Next step: Proof of Market | B2B2C | EUR 7Mn sought - France

Biotech/MedTech
Using small extracellular vesicles (exosomes) obtained from Umbilical Cord Blood as a therapeutic tool, our solution is developing a regenerative hydrogel to accelerate the healing of chronic wounds. The lead product under development, Exo-Wound, is a hydrogel that stimulates skin wound healing. The ultimate aim of this project is to demonstrate the safety and efficacy of Exo-Wound in human chronic wounds, strengthening its position for future licensing as a Wound Care player. Leveraging on the strong regenerative, anti-inflammatory, and immunomodulatory properties of the vesicles, we are enlarging its pipeline with products for other skin and autoimmune diseases. Customers: 3 | TRL: 6 | pre-Serie A | Next step: Commercial acceleration, Proof of Concept | EUR 5Mn sought - Portugal

MedTech
We are developing two medical devices at the moment. The BrachyDOSE for cancer treatment quality control and PIOAS for non-invasive COVID- 19 patients monitoring at home. BrachyDOSE was awarded by Horizon 2020 and EIT Health InnoStars Awards Grants. The PIOAS project was also supported by the Lithuanian Innovation Agency and EIT Health RIS Innovation funding. For BrachyDOSE we are preparing for the first human clinical trials at National Cancer Institute in Lithuania. While PIOAS is a younger project, we work on proof of concept with Santaros Clinics and Vilnius University. The BrachyDOSE startup was the winner of the Kaunas Startup Accelerator and participated in EIT Health and Roche-funded program. We are not on the market yet, but we already have first adopters in Heidelberg University Hospital, North Estonia Medical Centre, and National Cancer Institute in Lithuania. We are also partnering with Medicen Paris Region and Cubex startups incubator in Germany.
| TRL: 6 | TAM: EUR 2Bn | SAM: EUR 500MN | Pre-seed | B2B | EUR 2,8 Mn sought - Lithuania

Biotech, Pharma, drug discovery, preclinical models
BiomimX® is leveraging technology  to unlock in vitro preclinical models reflecting clinical complexity, towards the design of treatments tailored for patient. - Innovative Startup, Spinoff of Politecnico di Milano, established in 2017. 
- >725k€ already collected in non-dilutive money (3 H2020 projects, Seal of Excellence in EIC Accelerator, 7 national grants).
- Two key technological assets patented and proprietary: uBeat® (EP3289065B1, granted by EPO in 2019, by USA&China in 2021 and by India in 2022) and uSense (EP3620508B1, granted by EPO in 2021). Registered trademarks: uBeat® and BiomimX® in 2020. BiomimX is already on the market with its qualified models of complex diseases having successfully completed three pilots with Pharma/Biotech (>100k€ in revenues). 
Customers: 10 | TRL: 8 | TAM: EUR 200Bn | Turnover 2021: €25,000.00 | Seed | Next step: Commercial acceleration, Industrialisation EUR 5,0 Mn sought - Italy



Retail banking, energy, mobility
Decentralize data access control, giving it back to consumers and turning privacy laws from an obstacle into a new data monetization opportunity for companies in ‘traditional’ sectors.        
Patents granted in the US, Canada, and South Korea; notice of intention to grant received from the EPO. Patent applications filed in Japan and Singapore. Initial Clients in the retail banking and energy sectors. Signed partnership agreement with major system integrators. Awarded the 2021-2022 WomenTech EU prize 
| Women (co)founder| Customers: 3 |  TRL 7 (system prototype demonstration in operational environment). | TAM: €50Bn connected IoT devices in 2030 globally | SAM: Initial targets: banking, energy in EU; €243M energy meters and €392M banked in EU | Turnover 2021: €140,000.00 | pre-Serie A | Next step: Proof of Market | B2B2C | EUR 2,8 Mn sought - Italy  

 


EuroQuity - Blog

 
Stay informed by suscribing to our newsletter